Between an ugly truth and a perfect lie: Wiping off fearful memories using beta-adrenergic receptors antagonists

J Cell Physiol. 2019 May;234(5):5722-5727. doi: 10.1002/jcp.27441. Epub 2018 Nov 11.

Abstract

Psychiatric disorders such as anxiety, phobias, and post-traumatic stress disorder are considered of high global prevalence. Currently, a therapeutic approach to treat these disorders using beta-blockers, which antagonize the beta-adrenergic receptors (B1, B2, and B3) is being studied. This approach claims that beta-blockers, such as propranolol, inhibit fear memory reconsolidation. However, there are several studies refuting such claims by discrediting their experimental design and pointing out both the drugs pharmacokinetic properties and confounding factors. In this review, we explore the different effects of central beta-adrenergic agonists and antagonists on the fear memory consolidation providing mixed-evidence, limitations, and future directions.

Keywords: beta blockers; fear memories; reconsolidation.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / adverse effects
  • Adrenergic beta-Antagonists / pharmacokinetics
  • Adrenergic beta-Antagonists / therapeutic use*
  • Animals
  • Brain / drug effects*
  • Brain / metabolism
  • Brain / physiopathology
  • Fear / drug effects*
  • Humans
  • Memory Consolidation / drug effects*
  • Mental Disorders / drug therapy*
  • Mental Disorders / metabolism
  • Mental Disorders / physiopathology
  • Mental Disorders / psychology
  • Propranolol / adverse effects
  • Propranolol / pharmacokinetics
  • Propranolol / therapeutic use*
  • Stress Disorders, Post-Traumatic / drug therapy*
  • Stress Disorders, Post-Traumatic / metabolism
  • Stress Disorders, Post-Traumatic / physiopathology
  • Stress Disorders, Post-Traumatic / psychology

Substances

  • Adrenergic beta-Antagonists
  • Propranolol